Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Generation Bio Co. (NQ: GBIO )

3.000 -0.420 (-12.28%)
Streaming Delayed Price Updated: 1:41 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Generation Bio Co.

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Second Quarter 2023 Financial Results
Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025 
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 2023 Jefferies Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the JMP Securities Life Sciences Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Co. (NASDAQ: GBIO) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
From Generation Bio Co.; Moderna
Via GlobeNewswire
Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Cash balance of $301.2M expected to fund operations into 2025 
From Generation Bio Co.
Via GlobeNewswire
SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.